1. Antifungal prophylaxis in haematology patients: the role of voriconazole 
Y. Hicheri, G. Cook, C. Cordonnier 
Clinical Microbiology and Infection 
Volume 18, Pages 1-15 (April 2012)
DOI: /j x
Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1.
Kaplan–Meier estimates of fungal-free (proven/probable/presumptive) survival (a) and overall survival (b) up to 12 months in a large, randomized, controlled trial comparing voriconazole and fluconazole for primary prophylaxis of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients [34]. Reproduced with permission of the American Society of Hematology, from Wingard et al. [34]; permission conveyed through Copyright Clearance Center, Inc.
Clinical Microbiology and Infection  , 1-15DOI: ( /j x)
Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

3. FIG. 2.
Prophylactic success (composite endpoint combining fungal-free survival and sufficient duration of prophylaxis; adjusted for conditioning regimen and donor relatedness) at day 100 and day 180 in a large, randomized, controlled trial comparing voriconazole and itraconazole for primary prophylaxis of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients [32]. Voriconazole was superior (p <0.01) to itraconazole at both time points.
Clinical Microbiology and Infection  , 1-15DOI: ( /j x)
Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

4. FIG. 3.
Patient risk stratification and treatment recommendations for primary antifungal prophylaxis in haematology patients as per the ECIL-3 guidelines [56]. AmB, amphotericin B; GvHD, graft-versus-host disease; HCT, haematopoietic stem cell transplant; IV, intravenous.
Clinical Microbiology and Infection  , 1-15DOI: ( /j x)
Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions